Sangamo backs up early success for hemophilia gene therapy
The gene therapy era has arrived. So have the challenges.
Sangamo Shares Fall After Preliminary Gene Editing Data Only Shows Slight Benefit
As gene therapy gains traction, it is expected to create a number of job opportunities. For example, the UK government projects gene and cell therapy in Britain alone will create 18,000 new jobs by 2030. The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in … Συνεχίστε να διαβάζετε Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities.
FDA clears Vertex, CRISPR to test gene-editing therapy in sickle cell patients
Sangamo Therapeutics has agreed to acquire TxCell for €72 million ($84 million), the companies said today, in a deal designed to position the buyer as a leader in the development of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) cell therapies for immunological diseases. The planned acquisition, according to Sangamo, would accelerate the advancement of a CAR-Treg … Συνεχίστε να διαβάζετε Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition.
HIV research has come a long way since the disease was discovered in the 1980’s. Antiretroviral therapy was a major milestone that has changed the lives of millions, but the goal now is to find an HIV cure before 2020. We’ve scanned the biotech industry to identify the most promising developments towards finding the cure. … Συνεχίστε να διαβάζετε An HIV Cure by 2020? A Review of the Future of HIV Therapy.
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project (“HGP”), this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, genomic medicine is showing signs of being the transformative force that has been sought by Silicon Valley and DC politicians for many … Συνεχίστε να διαβάζετε Genomic Medicine: Catch The Gene Therapy Wave.
CRISPR stocks tank after research shows edited cells might cause cancer Shares of companies developing CRISPR-based therapies slid Monday after new research published in the journal Nature Medicine showed edited cells could cause cancer. Gene editing tool CRISPR-Cas9 has been hailed as a breakthrough that could allow scientists to treat and possibly even cure genetic … Συνεχίστε να διαβάζετε CRISPR stocks tank after research shows edited cells might cause cancer.